Dr Charon Lessing

profile image


Phone: ext 7870

Email: charon.lessing@aut.ac.nz

Physical Address:
North Shore Campus
90 Akoranga Drive
North Shore City
Postal Address:
Mail No. A-25
Private Bag 92006
Auckland 1142
New Zealand

ORCID: ORCID logo  https://orcid.org/0000-0002-3841-0334


PhD, MPH, MSc, BPharm(Hons)

Memberships and Affiliations:

  • Justice of the Peace NZ
  • Member of the New Zealand Pharmaceutical Society 


Dr Charon Lessing is a registered NZ pharmacist and lecturer in Pharmacology for Professional Practice at AUT. Charon holds master’s degrees in Social Pharmacy from the University of Copenhagen and in Public Health from the University of Auckland, and completed her PhD in 2015.

Originally from Zimbabwe, her interest focuses on access to medicines and their appropriate use. She has published on community participation in decision-making, consumer perspectives on funding of medicines, generic bioequivalence, pharmaceutical policy and direct-to-consumer marketing.

Research Areas:

Current research interests are centred on using ‘big data’ to monitor potential impacts, including clinical and economic outcomes of policy decisions. She also has a particular focus on pharmaceutical care of marginalised populations such as in mental health and people living with HIV.


  • Lessing C, Ashton T, Davis P. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference‐pricing: the case of lamotrigine in New Zealand. Appl. Health Econ Health Policy. 2014;12(5):537‐46.
  • Lessing C, Ashton T, Davis PB. An evaluation of health service impacts consequent to switching from brand to generic venlafaxine in New Zealand under conditions of price neutrality. Value in Health. 2015;18(5): 646–654.DOI: doi:10.1016/j.jval.2015.02.020
  • Lessing C, Ashton T, Davis PB. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment. Administration and Policy in Mental Health and Mental Health Services Research. 2014; 42 (6):695-703. DOI:10.1007/s10488-014-0606-9
  • Lessing C, Ashton T, Davis PB. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.  Journal of Primary Health Care. 2015; 7(2):94-101.
  • Lessing C, Ashton T, Davis PB. New Zealand patients’ understanding of brand-substitution and opinions on co-payment options for choice of medicine brand. Australian Health Review. 2016 Jun;40(3):345-50 (Published online: 14 September 2015).
  • Babar Z, Lessing C, Mace C, Bissell K. The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries. PharmacoEconomics. 2013;31(11):1063-82 DOI:10.1007/s40273-013-0095-9
  • Hasan RS, Lessing C. Pharmaceutical pricing policies in the Gulf Countries Council (GCC) and the United Arab Emirates (UAE). In: Babar Z, ed. Pharmaceutical Prices in the 21st Century. Springer International Publishing; 2015:297-307. DOI: 10.1007/978-3-319-12169-7_16.
  • Babar Z, Lessing C, Stewart J, Sheridan J. Evaluating general practitioners' opinions on issues concerning access to medicines in New Zealand. Journal of Pharmaceutical Health Services Research. 2015;6(3):145-154.
  • Babar Z, Polwin A, Kan SW, Amerasinghe N, McCarthy S, Rasheed F, Stewart J, Lessing C, Ragupathy R, Scahill SL. Exploring pharmacists' opinions regarding PHARMAC's interventions in promoting brand changes. Research in Social and Administrative Pharmacy. 2014; 11(1). DOI:10.1016/j.sapharm.2014.03.002
Website search